Articles tagged with Alzheimer Disease
Researchers identified a single gene, glutathione S-transferase omega-1 (GSTO1), as a key factor influencing the age of onset for both Alzheimer's and Parkinson's diseases. The study used genomic convergence to narrow down the genome region associated with age at onset, providing potential new targets for treatment.
A University of Pittsburgh study found that 22% of seniors over 75 have cognitive disorders, with multiple factors contributing to the condition. The study highlights the importance of good medical care in preventing brain disease and identifying risk factors for cognitive impairment.
A study by USC researchers found that engaging in leisure activities can lower the risk of developing Alzheimer's disease. Among female twin pairs, those who participated frequently in intellectually stimulating activities showed a reduced risk of Alzheimer's. The research controlled for genetics and early life experiences.
Primary progressive aphasia is a rare form of dementia that affects language abilities while preserving memory. Patients may struggle with word-finding and speaking, but can still recall recent events and maintain complex hobbies.
A study found that exercise combined with caregiver training can improve physical activity, reduce depression, and enhance physical health and function in people with Alzheimer's. Caregiver education also played a crucial role in the program's success.
Researchers at Saint Louis University have identified a protein transport deficit as a key factor in Alzheimer's disease. The study suggests that reversing this deficit could lead to a new therapeutic target for treating the condition.
A two-year study found that caregivers refuse risk-free medications to slow Alzheimer's disease progression if it may impact their relative's quality of life. Caregivers with depression, financial burdens, or from racial minority groups were more likely to decline treatment.
People with mild dementia decline faster than nondemented individuals in driving performance, but also some nondemented participants show decline. Longitudinal driving test every six months can identify those who become unsafe, increasing awareness about driving issues in demented persons and empowering families to intervene.
Researchers used a new microdialysis technique to study amyloid-beta levels in interstitial fluid and cerebrospinal fluid of mice with Alzheimer's-like changes. They found that ABeta42 levels decrease in cerebrospinal fluid while AB40 increases, suggesting a shift in how the molecule is moved between compartments.
A recent study suggests that menopause is not associated with an increase in cognitive decline, contrary to previous research. The Study of Women Across the Nation (SWAN) followed over 3,300 women across five ethnic groups, finding improved scores in most groups and minimal decline linked to menopause.
A study published in Pharmacology, Biochemistry and Behaviour found that sage oil improved word recall test performance in healthy young adults. Sage is being investigated as a potential treatment for Alzheimer's Disease due to its ability to inhibit the enzyme acetylcholinesterase.
Donepezil has been shown to improve cognitive function in vascular dementia patients, while a study found that brain volume loss can predict Alzheimer's disease. However, a clinical trial of topiramate in ALS patients found no benefits and an increased risk of adverse events.
Dronabinol significantly reduced agitation in 66% of Alzheimer's patients and improved functional status in 69%, while also addressing weight loss. These findings suggest dronabinol as a potential treatment option for managing behavioral symptoms in patients with Alzheimer's disease.
Studies link early life risk factors to dementia onset and suicidal tendencies in older adults. Drivers Rehabilitation Programs may improve elderly driver safety. Most doctors fail to recognize early signs of Alzheimer's and cognitive impairment in their patients.
Researchers estimate that by mid-century, up to 16 million Americans will have Alzheimer's disease, with significant increases in prevalence among the oldest age group. Increasing funding for research is critical to prevent the disease or delay its onset and avoid devastating economic costs.
Researchers have found small, soluble aggregated proteins called ADDLs in the brains of individuals with Alzheimer's disease, up to 70 times more than in normal individuals. These proteins may be reversibly blocking memory function, providing a potential target for new therapeutic drugs.
The study estimates that the national prevalence of Alzheimer's disease will increase significantly by 2050, with 60% of cases projected to affect people 85 and older. This is due to declining death rates after age 65, allowing more people to survive to older ages where the risk of AD is highest.
Studies found that patients with vascular dementia had less NAA in regions involved in short-term memory and language, while those with Alzheimer's had substantial NAA deficits. Accuracy improved when combining MRI and MR spectroscopy measures, suggesting potential for recovery through drug treatment.
A study reveals that elderly humans and patients with Alzheimer's disease exhibit increased T cell reactivity towards Abeta, a protein linked to the aging process. This selective increase in Abeta-reactivity has implications for developing Abeta vaccines and may be connected to disease susceptibility and progression.
Researchers have found that the enzyme Pin1 plays a crucial role in protecting neurons from age-related degeneration and tangle formation in Alzheimer's patients. By understanding how Pin1 works, scientists hope to develop new therapies to prevent or slow down neurodegenerative processes.
Researchers found an inverse relationship between Pin1 abundance and degenerative damage susceptibility. Pin1-deficient mice developed a neurodegenerative disease similar to Alzheimer's, highlighting the protein's role in regulating proteins critical for cell division.
Researchers have created a triple-transgenic mouse that exhibits both plaque and tangle lesions, allowing them to study the relationship between the two and develop drugs targeting both. This model could lead to a single class of drugs for treating both inherited and sporadic forms of Alzheimer's disease.
UCSB scientists propose a new model for neuronal cell death in Alzheimer's disease, suggesting tau dysfunction leads to abnormal microtubule dynamics. This new theory has important implications for developing effective drugs to treat the disease.
Recent studies establish that beta-amyloid activates caspases, cutting tau at its tangle-blocking end and generating abnormal filaments. This process occurs before neuronal apoptosis, promoting death of the neuron.
Researchers found that caspase cleavage of tau promotes the formation of abnormal filaments resembling tangles. This discovery provides a new link between amyloid-beta and tau tangles, suggesting a common cause for Alzheimer's disease.
A study led by Constantine Lyketsos found that sertraline hydrochloride significantly improved the quality of life and reduced functional decline in Alzheimer's patients with depression. The treatment showed a positive influence on 84% of participants, while only 35% in the placebo group experienced improvements.
A study found that Alzheimer's disease alters a protein called calbindin in brain cells, leading to cognitive deficits. Calbindin levels in granule cells were strongly correlated with cognitive decline in genetically engineered mice and human patients.
Women who developed Alzheimer's disease between ages 79 and 88 were significantly more likely to have been overweight at age 70. A moderate, healthy weight seems to be best according to the study.
A new study published in the Journal of Clinical and Experimental Neuropsychology found that higher education or a larger brain size may help delay dementia. The research, based on data from the Nun Study, suggests that having more years of formal education or better early brain development can provide extra reserve for cognitive funct...
Researchers identified a previously unknown protein family, chaplins A-H, essential for S. coelicolor's aerial hyphae formation. Exogenous application of chaplin proteins restores aerial growth in streptomycetes lacking specific genes.
Research reveals that amyloid accumulation selectively reduces expression of genes essential for forming new memories, leading to early memory loss in Alzheimer's disease. The study suggests a new approach to treating the disease by blocking the effect of remaining amyloid on normal learning and memory.
Researchers discuss new findings on HIV-associated dementia and its potential association with the presence of MDM. Additionally, studies suggest that treating post-Lyme disease with antibiotics does not provide benefits, while a possible link is found between insulin and Alzheimer's disease risk factors.
Researchers at Rush University Medical Center found that higher education is associated with better memory and learning ability in individuals with Alzheimer's disease. The study, published in Neurology, suggests that formal education may provide a cognitive reserve that reduces the effects of AD brain abnormalities.
Research suggests that individuals with higher education levels exhibit less cognitive decline in Alzheimer's disease due to increased brain adaptability and flexibility. The study, which analyzed autopsied brains of deceased participants, found a significant association between education and reduced AD pathology.
Researchers discover that Alzheimer's protein amyloid beta is transported into the brain by riding piggyback on a larger molecule called RAGE. This discovery opens up new possibilities for treating the disease. By blocking RAGE, blood flow to the brain can be restored and amyloid plaques reduced.
Researchers discovered that patients who received Exelon before withdrawing from a study showed significantly less cognitive decline than placebo-treated patients. The findings suggest a possible effect in delaying the biological progression of Alzheimer's disease.
A new NIH-funded study found that low-dose naproxen and rofecoxib do not slow cognitive decline in patients with mild-to-moderate Alzheimer's disease. In fact, patients taking rofecoxib experienced more rapid cognitive decline than those on placebo or naproxen.
Researchers found that women taking estrogen and progestin experienced a twice increased risk of dementia compared to those on placebo pills over a 5-year period. The most common type of dementia was probable Alzheimer's disease, accounting for 66% of cases.
Rotarians have awarded Penn a $250,000 grant for Alzheimer's research using funds from their Coins for Alzheimer's Research Trust. This grant builds on the work of Domenico Praticó, who has identified isoprostanes as a promising new avenue for treating Alzheimer's disease.
Researchers found that lithium significantly reduces production of beta amyloid, a key component of Alzheimer's disease. The study suggests that combination therapy with lithium and non-steroidal anti-inflammatory drugs may have an enhanced effect in reducing amyloid peptide accumulation.
Researchers at Northwestern University find brain tangles in normal aging and mild cognitive impairment, correlating with memory loss. Neurofibrillary tangles are more numerous in brain regions associated with memory function, suggesting a link between tangle density and memory performance.
Researchers are testing a new stroke prevention drug, NC-758, to determine its effectiveness in reducing amyloid angiopathy-related strokes. The trial aims to assess the drug's potential benefits for patients with Alzheimer's disease, which is characterized by excessive amyloid buildup.
Researchers have discovered that mouse models of Alzheimer's disease duplicate their DNA and make an attempt at cell division, just like human nerve cells. This suggests that the underlying mechanism of cell death is the same in both species, potentially making these model systems more suitable for testing experimental therapies.
Researchers at UCSB discovered a connection between Alzheimer's disease and age-related macular degeneration, both linked to the presence of inflammatory plaques. The study suggests that a toxic protein called amyloid beta may be the underlying culprit, stimulating an inflammation process that contributes to vision loss.
Researchers used MR imaging to compare Alzheimer's patients' brains with those of children and adults, finding similar water molecule diffusion. The technique may help detect white matter disease earlier in dementia.
A study published in Proceedings of the National Academy of Sciences found a relationship between insulysin and Alzheimer's disease. The researchers discovered that even partial decreases in insulysin activity raised amyloid-beta peptide levels in the brain, increasing the risk of Alzheimer's.
A study found that enhanced counseling and support interventions significantly reduced depression symptoms in caregivers, with benefits sustained over a 5-year period. The intervention involved individual and family counseling sessions, as well as ongoing support groups.
Researchers at Case Western Reserve University discovered molecules that play a critical role in triggering inflammation in the brain, which speeds up Alzheimer's disease progression. The study found that blocking these molecules' interaction with amyloid plaques could lead to a slower disease progression.
In a study, mice fasted every other day had lower blood glucose and insulin levels than control or calorically restricted groups. Meal-skipping also improved nerve cell resistance to neurotoxin injury, suggesting potential benefits for neurological disorders such as Alzheimer's disease.
A new study has found that cerebrospinal fluid biomarkers may be effective in detecting early stages of Alzheimer's disease, with a sensitivity of 92% and specificity of 89%. The researchers suggest that these biomarkers could be used to identify people at risk of developing the disease.
Researchers found that participants taking statins lowered their brain cholesterol levels by 21.4 percent, potentially reducing amyloid plaque formation and severity of Alzheimer's disease. The study, led by Dr. Gloria Vega, showed no adverse side effects in patients with normal cholesterol levels.
The report, endorsed by national not-for-profit research organizations, urges a 10% increase in the NIH budget to address Alzheimer's, diabetes, and arthritis. This investment could lead to major medical advances and alleviate suffering from aging-related diseases.
New research presented at the AAN Annual Meeting includes promising treatments for MS, potential therapeutic targets for worsening ataxia in ALS, and a connection between Chlamydia infection and increased stroke risk. Statins also show promise in reducing cognitive decline and improving recovery from stroke.
A 50-amino-acid stretch of the amyloid precursor protein (APP) jams mitochondria and endoplasmic reticulum, starving cells of energy. This leads to neuronal death, a hallmark of Alzheimer's disease, according to Penn researchers.
Researchers found A-beta plaques in lenses from Alzheimer's patients, similar to those in brain tissue. The discovery could lead to a non-invasive test for disease diagnosis and tracking.
Researchers found that DHEA did not significantly improve cognitive performance or ratings of disease severity in a randomized, double-blind trial. The study's small size and high drop-out rate may limit the findings, with larger studies needed to confirm the results.
A new analysis of the Moderate to Severe Alzheimer's Disease Study (MSAD) found that ARICEPT significantly improved global function, cognition, and activities of daily living in patients with severe Alzheimer's disease. The study showed that ARICEPT also reduced behavioral symptoms associated with the disease.
A study showed that ARICEPT, a leading Alzheimer's treatment, is also effective in treating vascular dementia (VaD). Patients with VaD who received ARICEPT demonstrated significant improvements in cognition and daily living activities. The study suggests that ARICEPT may be an important measure of treatment success for VaD patients.
Two new studies presented at the American Academy of Neurology meeting found that ARICEPT treatment improved cognition in patients with mild cognitive impairment (MCI) and reduced behavioral symptoms in those with Parkinson's-related dementia. These findings provide encouraging news for millions of Americans affected by MCI.
Memantine, a new drug, has been found to slow the mental and physical deterioration of patients with moderate to severe Alzheimer's disease. The study, led by Dr. Barry Reisberg, showed that patients taking memantine experienced significantly less decline in cognition and daily life activities compared to those receiving a placebo.